Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Next Pharmaceuticals' Nexrutine To Be Studied, Forms Agreement With Wilke Resources - Nutraceuticals World

What are you searching for?

Sign in
Market Updates

Next Pharmaceuticals’ Nexrutine To Be Studied, Forms Agreement With Wilke Resources

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

AMC Cancer Research Center, Denver, CO, has been awarded a two-year grant from the National Institutes of Health (NIH), Bethesda, MD, to study Nexrutine® as a prostate cancer preventative agent and to determine the molecular mechanism that underlies its efficacy. Nexrutine is a natural anti-inflammatory ingredient developed by Next Pharmaceuticals, Irvine, CA, for use in dietary supplements. It is a patent-pending plant extract from the bark of Phellodendron trees commonly found in Asia.

In other news, the company has entered into an agreement with Wilke Resources, Lenexa, KS, wherein Wilke will act as the exclusive U.S. sales agent for Next’s flagship products, Relora® and Nexrutine.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters

Topics